Efinopegdutide is another GLP-1R and GCGR dual agonist currently under clinical investigation, which is being explored in studies for patients with obesity, type 2 diabetes (T2D), and metabolically associated fatty liver disease/multiple acyl-CoA dehydrogenase deficiency syndrome (MASLD/MASH)
The Summary of Product Characteristics (SmPC) for Wegovy does not list gout or hyperuricaemia (elevated uric acid levels) among the documented side effects
At present, the main treatment methods for myopenia include nutritional intervention, resistance training, drug therapy, and comprehensive management strategies [10]
Additionally, weight loss can help improve glycemic control, making GLP-1 medications particularly valuable for individuals with both obesity and type 2 diabetes
For many, a combination of both alongside proper diet and resistance training delivers the most balanced results